Sageworth Trust Co Trims Stock Position in Johnson & Johnson (NYSE:JNJ)

Sageworth Trust Co decreased its stake in Johnson & Johnson (NYSE:JNJ) by 45.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,241 shares of the company’s stock after selling 3,536 shares during the quarter. Sageworth Trust Co’s holdings in Johnson & Johnson were worth $613,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. AMF Tjanstepension AB boosted its position in Johnson & Johnson by 14.2% during the third quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock worth $68,985,000 after purchasing an additional 52,997 shares in the last quarter. Alpha Financial Partners LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $209,000. Wealth Group Ltd. acquired a new stake in Johnson & Johnson in the 3rd quarter valued at $213,000. Rise Advisors LLC increased its holdings in Johnson & Johnson by 3.2% in the 3rd quarter. Rise Advisors LLC now owns 3,134 shares of the company’s stock worth $508,000 after acquiring an additional 96 shares in the last quarter. Finally, Willis Investment Counsel raised its position in Johnson & Johnson by 0.3% during the third quarter. Willis Investment Counsel now owns 308,892 shares of the company’s stock worth $50,059,000 after acquiring an additional 863 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on JNJ. Barclays boosted their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. Morgan Stanley reduced their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Leerink Partners lowered their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Wells Fargo & Company decreased their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Finally, Citigroup dropped their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $170.67.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $154.22 on Tuesday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The stock has a market cap of $371.31 billion, a price-to-earnings ratio of 23.19, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. The business has a fifty day moving average of $147.42 and a two-hundred day moving average of $156.08.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same period last year, the company earned $2.29 EPS. The company’s quarterly revenue was up 5.3% on a year-over-year basis. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.22%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.